Autoimmune Pipeline And Late Stage Blockbusters Will Face Relentless Competition And Margin Pressure

Catalysts

About Roivant Sciences

Roivant Sciences develops and commercializes pharmaceutical assets, including late stage autoimmune and rare disease therapies, and pursues licensing for its lipid nanoparticle technology.

What are the underlying business or industry changes driving this perspective?

• Although brepocitinib is positioned for an NDA filing in dermatomyositis with strong late stage data and potential first oral status in this indication, future revenue relies on successful approval and execution in an orphan market where physician adoption curves and access terms are still uncertain. This could temper the pace of revenue ramp and earnings contribution.
• While IMVT-1402 is moving through a broad registrational program across Graves' disease, myasthenia gravis, CIDP, difficult to treat rheumatoid arthritis, Sjögren's and other autoimmune conditions, this breadth demands sustained R&D spend and complex trial execution. Any delay or mixed result in key indications could weigh on net margins and push out the timing of earnings scalability.
• Although the increasing medical focus on autoimmune and rare immune mediated diseases creates room for therapies that reduce steroid burden and target disease drivers such as autoantibodies, Roivant faces multiple competitors in areas like Graves' disease and myasthenia gravis. Intense competition for similar patient pools may limit pricing power and constrain long term margin expansion.
• Despite the broadening use of biologics and FcRn modulators in chronic immune conditions, payers are becoming more focused on cost and durability of response. As a result, products like batoclimab and IMVT-1402 may need to show clear health economic benefits alongside efficacy, which could influence negotiated net pricing, rebate levels and ultimately the trajectory of operating margins.
• While the global spread of mRNA and other nucleic acid platforms supports continued relevance of Genevant's lipid nanoparticle IP and creates potential for licensing income, litigation outcomes and timing remain uncertain. Any royalty or settlement cash flows are difficult to factor into a stable earnings base and may be treated by investors as non recurring rather than core revenue.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Roivant Sciences compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Roivant Sciences's revenue will grow by 458.6% annually over the next 3 years.
• The bearish analysts are not forecasting that Roivant Sciences will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Roivant Sciences's profit margin will increase from -3629.2% to the average US Biotechs industry of 17.2% in 3 years.
• If Roivant Sciences's profit margin were to converge on the industry average, you could expect earnings to reach $247.7 million (and earnings per share of $0.29) by about July 2029, up from -$299.8 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.2 billion in earnings, and the most bearish expecting $-1.1 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 133.1x on those 2029 earnings, up from -82.8x today. This future PE is greater than the current PE for the US Biotechs industry at 17.3x.
• The bearish analysts expect the number of shares outstanding to grow by 5.33% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.57%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The company has 11 late stage programs that management describes as having blockbuster potential and is preparing for a series of product launches over the next 36 months. If multiple approvals are granted and launches scale, that could support higher revenue and earnings than implied by a flat share price view.
• Brepocitinib in dermatomyositis hit all ranked endpoints in Phase III and is being prepared for an NDA filing as a potential first novel oral therapy in a population with high unmet need and limited existing options. If physician uptake and pricing in this orphan segment are favorable, that could support a stronger revenue ramp and improve net margins.
• IMVT-1402 is already in potentially registrational trials across Graves' disease, myasthenia gravis, CIDP, difficult to treat rheumatoid arthritis, Sjögren's and cutaneous lupus, and management highlights large patient pools with many uncontrolled on current treatments. Broad success across even a subset of these indications could materially increase long term revenue and operating earnings.
• Management repeatedly points to the scale of the uncontrolled Graves' disease population and compares the opportunity to what FcRn therapies have achieved in myasthenia gravis. If uptake in Graves' approaches other FcRn use cases, that could support a step change in revenue and shift the company closer to sustained profitability.
• Roivant reports US$4.4b in cash and no debt and states this capital is expected to support the current pipeline to profitability and allow for pipeline expansion and potential additional capital return. If this balance sheet strength is used to advance more assets successfully or return more capital, that could improve long term earnings power and influence the valuation multiple applied to the shares.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Roivant Sciences is $31.5, which represents up to two standard deviations below the consensus price target of $39.32. This valuation is based on what can be assumed as the expectations of Roivant Sciences's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $49.0, and the most bearish reporting a price target of just $31.5.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.4 billion, earnings will come to $247.7 million, and it would be trading on a PE ratio of 133.1x, assuming you use a discount rate of 7.6%.
• Given the current share price of $34.51, the analyst price target of $31.5 is 9.6% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.